A potential paradigm shift in opioid crisis management: The role of pharmacogenomics

References

• Alexander GC, Stoller KB, Haffajee RL, Saloner B. 2020. An epidemic in the midst of a pandemic: opioid use disorder and COVID-19. Ann Intern Med. 173(1):57–58.
   PubMed Web of Science ®Google Scholar
• Althobaiti YS, Alzahrani MA, Alsharif NA, Alrobaie NS, Alsaab HO, Uddin MN. 2020. The possible relationship between the abuse of tobacco, opioid, or alcohol with COVID-19. Healthcare. 9(1):2.
   Web of Science ®Google Scholar
• Bains RK, Kovacevic M, Plaster CA, Tarekegn A, Bekele E, Bradman NN, Thomas MG. 2013. Molecular diversity and population structure at the Cytochrome P450 3A5 gene in Africa. BMC Genet. 14:34.
   PubMed Web of Science ®Google Scholar
• Barratt DT, Bandak B, Klepstad P, Dale O, Kaasa S, Christrup LL, Tuke J, Somogyi AA. 2014. Genetic, pathological and physiological determinants of transdermal fentanyl pharmacokinetics in 620 cancer patients of the EPOS study. Pharmacogenet Genomics. 24(4):185–194.
   PubMed Web of Science ®Google Scholar
• Becker WC, Fiellin DA. 2020. When epidemics collide: coronavirus disease 2019 (COVID-19) and the opioid crisis. Ann Intern Med. 173(1):59–60.
   PubMed Web of Science ®Google Scholar
• Blanco F, Muriel C, Labrador J, Gonzalez-Porras JR, Gonzalez-Sarmiento R, Lozano FS. 2016. Influence of UGT2B7, CYP3A4, and OPRM1 gene polymorphisms on transdermal buprenorphine pain control in patients with critical lower limb ischemia awaiting revascularization. Pain Pract. 16(7):842–849.
   PubMed Web of Science ®Google Scholar
• Burns JA, Kroll DS, Feldman DE, Kure Liu C, Manza P, Wiers CE, Volkow ND, Wang GJ. 2019. Molecular imaging of opioid and dopamine systems: insights into the pharmacogenetics of opioid use disorders. Front Psychiatry. 10:626.
   PubMed Web of Science ®Google Scholar
• Caraco Y, Sheller J, Wood AJ. 1996. Pharmacogenetic determination of the effects of codeine and prediction of drug interactions. J Pharmacol Exp Ther. 278(3):1165–1174.
   PubMed Web of Science ®Google Scholar
• Cdcgov. 2020a. Increase in fatal drug overdoses across the united states driven by synthetic opioids before and during the COVID-19 pandemic. Health Alert Network (HAN), 438.
   Google Scholar
• Cdcgov. 2020b. Mental health, substance use, and suicidal ideation during the COVID-19 pandemic — United States, June 24–30, 2020|MMWR.
   Google Scholar
• Cdcgov. 2021. Products – vital statistics rapid release – provisional drug overdose data.
   Google Scholar
• Chartoff EH, McHugh RK. 2016. Translational studies of sex differences in sensitivity to opioid addiction. Neuropsychopharmacology. 41(1):383–384.
   PubMed Web of Science ®Google Scholar
• Chong RY, Oswald L, Yang X, Uhart M, Lin PI, Wand GS. 2006. The mu-opioid receptor polymorphism A118G predicts cortisol responses to naloxone and stress. Neuropsychopharmacol. 31(1):204–211.
   PubMed Web of Science ®Google Scholar
• Christie MJ. 2008. Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and addiction. Br J Pharmacol. 154(2):384–396.
   PubMed Web of Science ®Google Scholar
• Clarke TK, Weiss AR, Ferarro TN, Kampman KM, Dackis CA, Pettinati HM, O'brien CP, Oslin DW, Lohoff FW, Berrettini WH. 2014. The dopamine receptor D2 (DRD2) SNP rs1076560 is associated with opioid addiction. Ann Hum Genet. 78(1):33–39.
   PubMed Web of Science ®Google Scholar
• Crews KR, Gaedigk A, Dunnenberger HM, Leeder JS, Klein TE, Caudle KE, Haidar CE, Shen DD, Callaghan JT, Sadhasivam S, et al. 2014. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharmacol Ther. 95(4):376–382.
   PubMed Web of Science ®Google Scholar
• Crews KR, Monte AA, Huddart R, Caudle KE, Kharasch ED, Gaedigk A, Dunnenberger HM, Leeder JS, Callaghan JT, Samer CF, et al. 2021. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6, OPRM1, and COMT genotypes and select opioid therapy. Clin Pharmacol Ther. 110(4):888–896.
   PubMed Web of Science ®Google Scholar
• Crist RC, Clarke TK, Ang A, Ambrose-Lanci LM, Lohoff FW, Saxon AJ, Ling W, Hillhouse MP, Bruce RD, Woody G, et al. 2013. An intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-Americans. Neuropsychopharmacology. 38(10):2003–2010.
   PubMed Web of Science ®Google Scholar
• Crist RC, Li J, Doyle GA, Gilbert A, Dechairo BM, Berrettini WH. 2018. Pharmacogenetic analysis of opioid dependence treatment dose and dropout rate. Am J Drug Alcohol Abuse. 44(4):431–440.
   PubMed Web of Science ®Google Scholar
• Crist RC, Phillips KA, Furnari MA, Moran LM, Doyle GA, McNicholas LF, Cornish JW, Kampman KM, Preston KL, Berrettini WH. 2019. Replication of the pharmacogenetic effect of rs678849 on buprenorphine efficacy in African-Americans with opioid use disorder. Pharmacogenomics J. 19(3):260–268.
   PubMed Web of Science ®Google Scholar
• Dahan A, Aarts L, Smith TW. 2010. Incidence, reversal, and prevention of opioid-induced respiratory depression. Anesthesiology. 112(1):226–238.
   PubMed Web of Science ®Google Scholar
• Esposito E, Di Matteo V, Di Giovanni G. 2008. Serotonin-dopamine interaction: an overview. Prog Brain Res. 172:3–6.
   PubMed Web of Science ®Google Scholar
• Fudin J, Atkinson TJ. 2014. Personalized oxycodone dosing: using pharmacogenetic testing and clinical pharmacokinetics to reduce toxicity risk and increase effectiveness. Pain Med. 15(5):723–725.
   PubMedGoogle Scholar
• Fukuda K, Hayashida M, Ide S, Saita N, Kokita Y, Kasai S, Nishizawa D, Ogai Y, Hasegawa J, Nagashima M, et al. 2009. Association between OPRM1 gene polymorphisms and fentanyl sensitivity in patients undergoing painful cosmetic surgery. Pain. 147(1–3):194–201.
   PubMed Web of Science ®Google Scholar
• Gaedigk A, Sangkuhl K, Whirl-Carrillo M, Klein T, Leeder JS. 2017. Prediction of CYP2D6 phenotype from genotype across world populations. Genet Med. 19(1):69–76.
   PubMed Web of Science ®Google Scholar
• Gerhard GS, Kaniper S, Paynton B. 2020. Fentanyl overdoses and pharmacogenetics. Pharmacogenet Genomics. 30(1):5–8.
   PubMed Web of Science ®Google Scholar
• Green TC, Bratberg J, Finnell DS. 2020. Opioid use disorder and the COVID 19 pandemic: a call to sustain regulatory easements and further expand access to treatment. Subst Abus. 41(2):147–149.
   PubMed Web of Science ®Google Scholar
• Hassan HE, Myers AL, Coop A, Eddington N,D. 2009. Differential involvement of P-glycoprotein (ABCB1) in permeability, tissue distribution, and antinociceptive activity of methadone, buprenorphine, and diprenorphine: in vitro and in vivo evaluation. J Pharm Sci. 98(12):4928–4940.
   PubMed Web of Science ®Google Scholar
• Huang P, Kehner GB, Cowan A, Liu-Chen LY. 2001. Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther. 297(2):688–695.
   PubMed Web of Science ®Google Scholar
• Jalabert M, Bourdy R, Courtin J, Veinante P, Manzoni OJ, Barrot M, Georges F. 2011. Neuronal circuits underlying acute morphine action on dopamine neurons. Proc Natl Acad Sci USA. 108(39):16446–16450.
   PubMed Web of Science ®Google Scholar
• Jenkins WD, Bolinski R, Bresett J, Van Ham B, Fletcher S, Walters S, Friedman SR, Ezell JM, Pho M, Schneider J, et al. 2021. COVID-19 during the opioid epidemic – exacerbation of stigma and vulnerabilities. J Rural Health. 37(1):172–174.
   PubMed Web of Science ®Google Scholar
• Jing Li J, Szkudlarek H, Renard J, Hudson R, Rushlow W, Laviolette SR. 2018. Fear memory recall potentiates opiate reward sensitivity through dissociable dopamine D1 versus D4 receptor-dependent memory mechanisms in the prefrontal cortex. J Neurosci. 38(19):4543–4555.
   PubMed Web of Science ®Google Scholar
• Kalivas PW, Volkow ND. 2005. The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry. 162(8):1403–1413.
   PubMed Web of Science ®Google Scholar
• Khatri UG, Perrone J. 2020. Opioid use disorder and COVID-19: crashing of the crises. J Addict Med. 14(4):e6–e7.
   PubMed Web of Science ®Google Scholar
• Kuip EJ, Zandvliet ML, Koolen SL, Mathijssen RH, van der Rijt CC. 2017. A review of factors explaining variability in fentanyl pharmacokinetics; focus on implications for cancer patients. Br J Clin Pharmacol. 83(2):294–313.
   PubMed Web of Science ®Google Scholar
• Kumar S, Kundra P, Ramsamy K, Surendiran A. 2019. Pharmacogenetics of opioids: a narrative review. Anaesthesia. 74(11):1456–1470.
   PubMed Web of Science ®Google Scholar
• Lee MG, Kim HJ, Lee KH, Choi YS. 2016. The influence of genotype polymorphism on morphine analgesic effect for postoperative pain in children. Korean J Pain. 29(1):34–39.
   PubMed Web of Science ®Google Scholar
• Leen JLS, Juurlink DN. 2019. Carfentanil: a narrative review of its pharmacology and public health concerns. Can J Anesth. 66(4):414–421.
   PubMed Web of Science ®Google Scholar
• Liao MZ, Gao C, Shireman LM, Phillips B, Risler LJ, Neradugomma NK, Choudhari P, Prasad B, Shen DD, Mao Q. 2017. P-gp/ABCB1 exerts differential impacts on brain and fetal exposure to norbuprenorphine. Pharmacol Res. 119:61–71.
   PubMed Web of Science ®Google Scholar
• LLerena A, Naranjo ME, Rodrigues-Soares F, Penas LEM, Fariñas H, Tarazona S. 2014. Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations. Expert Opin Drug Metab Toxicol. 10(11):1569–1583.
   PubMed Web of Science ®Google Scholar
• Lloyd RA, Hotham E, Hall C, Williams M, Suppiah V. 2017. Pharmacogenomics and patient treatment parameters to opioid treatment in chronic pain: a focus on morphine, oxycodone, tramadol, and fentanyl. Pain Med. 18(12):2369–2387.
   PubMed Web of Science ®Google Scholar
• Madadi P, Amstutz U, Rieder M, Ito S, Fung V, Hwang S, Turgeon J, Michaud V, Koren G, Carleton BC. 2018. Clinical practice guideline: CYP2D6 genotyping for safe and efficacious codeine therapy. https://jptcpcom/indexphp/jptcp
   Google Scholar
• Maglione MA, Raaen L, Chen C, Azhar G, Shahidinia N, Shen M, Maksabedian E, Shanman RM, Newberry S, Hempel S. 2018. Effects of medication assisted treatment (MAT) for opioid use disorder on functional outcomes: a systematic review. J Subst Abuse Treat. 89:28–51.
   PubMed Web of Science ®Google Scholar
• Maiti T, Das S, Ramasamy A, Stanley Xavier A, Kumar Behera S, Selvarajan S. 2020. An overview on medication-assisted treatment (MAT) for opioid dependence. J Opioid Manag. 16(2):141–149.
   PubMedGoogle Scholar
• Margarit C, Roca R, Inda MD, Muriel J, Ballester P, Moreu R, Conte AL, Nuñez A, Morales D, Peiró AM. 2019. Genetic contribution in low back pain: a prospective genetic association study. Pain Pract. 19(8):836–847.
   PubMed Web of Science ®Google Scholar
• Massaly N, Copits BA, Wilson-Poe AR, Hipólito L, Markovic T, Yoon HJ, Liu S, Walicki MC, Bhatti DL, Sirohi S, et al. 2019. Pain-induced negative affect is mediated via recruitment of the nucleus accumbens kappa opioid system. Neuron. 102(3):564–573.
   PubMed Web of Science ®Google Scholar
• Matsui A, Jarvie BC, Robinson BG, Hentges ST, Williams JT. 2014. Separate GABA afferents to dopamine neurons mediate acute action of opioids, development of tolerance, and expression of withdrawal. Neuron. 82(6):1346–1356.
   PubMed Web of Science ®Google Scholar
• Meyer MR, Maurer HH. 2011. Absorption, distribution, metabolism and excretion pharmacogenomics of drugs of abuse. Pharmacogenomics. 12(2):215–233.
   PubMed Web of Science ®Google Scholar
• Mura E, Govoni S, Racchi M, Carossa V, Ranzani GN, Allegri M, van Schaik RH. 2013. Consequences of the 118A > G polymorphism in the OPRM1 gene: translation from bench to bedside? J Pain Res. 6:331–353.
   PubMed Web of Science ®Google Scholar
• Muriel J, Margarit C, Barrachina J, Ballester P, Flor A, Morales D, Horga JF, Fernández E, Peiró AM. 2019. Pharmacogenetics and prediction of adverse events in prescription opioid use disorder patients. Basic Clin Pharmacol Toxicol. 124(4):439–448.
   PubMed Web of Science ®Google Scholar
• Naito T, Takashina Y, Yamamoto K, Tashiro M, Ohnishi K, Kagawa Y, Kawakami J. 2011. CYP3A5*3 affects plasma disposition of noroxycodone and dose escalation in cancer patients receiving oxycodone. J Clin Pharmacol. 51(11):1529–1538.
   PubMed Web of Science ®Google Scholar
• Ncbi 2021. International HapMap Project. [accessed]. http://hapmap.ncbi.nlm.nih.gov.
   Google Scholar
• Ning M, Tao Y, Hu X, Guo L, Ni J, Hu J, Shen H, Chen Y. 2019. Roles of UGT2B7 C802T gene polymorphism on the efficacy of morphine treatment on cancer pain among the Chinese Han population. Niger J Clin Pract. 22(10):1319–1323.
   PubMed Web of Science ®Google Scholar
• Owusu Obeng A, Hamadeh I, Smith M. 2017. Review of opioid pharmacogenetics and considerations for pain management. Pharmacotherapy. 37(9):1105–1121.
   PubMed Web of Science ®Google Scholar
• Pelkowski J. 2020. Pharmacogenetic considerations in opioid therapy prescribing. J Nurse Pract. 16(3):201–204.
   Google Scholar
• Reynolds KK, Ramey-Hartung B, Jortani SA. 2008. The value of CYP2D6 and OPRM1 pharmacogenetic testing for opioid therapy. Clin Lab Med. 28(4):581–598.
   PubMed Web of Science ®Google Scholar
• Rocco R, Thiels CA, Ubl DS, Moyer AM, Habermann EB, Cassivi SD. 2019. Use of pharmacogenetic data to guide individualized opioid prescribing after surgery. Surgery. 166(4):476–482.
   PubMed Web of Science ®Google Scholar
• Rodriguez CF, Appiani F, Sambade JM, Comandé D, Camacho Arteaga L, Ciapponi A. 2021. Efficacy and safety of opioid therapy guided by pharmacogenetics: a systematic review. Pharmacogenomics. 22(9):573–586.
   PubMed Web of Science ®Google Scholar
• Ruano G, Kost JA. 2018. Fundamental considerations for genetically-guided pain management with opioids based on CYP2D6 and OPRM1 polymorphisms. Pain Physician. 21(6):E611–E621.
   PubMed Web of Science ®Google Scholar
• Russo SJ, Bolanos CA, Theobald DE, DeCarolis NA, Renthal W, Kumar A, Winstanley CA, Renthal NE, Wiley MD, Self DW, et al. 2007. IRS2-Akt pathway in midbrain dopamine neurons regulates behavioral and cellular responses to opiates. Nat Neurosci. 10(1):93–99.
   PubMed Web of Science ®Google Scholar
• Saiz-Rodríguez M, Ochoa D, Herrador C, Belmonte C, Román M, Alday E, Koller D, Zubiaur P, Mejía G, Hernández-Martínez M, et al. 2019. Polymorphisms associated with fentanyl pharmacokinetics, pharmacodynamics and adverse effects. Basic Clin Pharmacol Toxicol. 124(3):321–329.
   PubMed Web of Science ®Google Scholar
• Samer CF, Daali Y, Wagner M, Hopfgartner G, Eap CB, Rebsamen MC, Rossier MF, Hochstrasser D, Dayer P, Desmeules JA. 2010. The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone. Br J Pharmacol. 160(4):907–918.
   PubMed Web of Science ®Google Scholar
• Sastre JA, Varela G, López M, Muriel C, González-Sarmiento R. 2015. Influence of uridine diphosphate-glucuronyltransferase 2B7 (UGT2B7) variants on postoperative buprenorphine analgesia. Pain Pract. 15(1):22–30.
   PubMed Web of Science ®Google Scholar
• Sekhri NK, Cooney MF. 2017. Opioid metabolism and pharmacogenetics: clinical implications. J Perianesth Nurs. 32(5):497–505.
   PubMed Web of Science ®Google Scholar
• Singh A, Zai C, Mohiuddin AG, Kennedy JL. 2020. The pharmacogenetics of opioid treatment for pain management. J Psychopharmacol. 34(11):1200–1209.
   PubMed Web of Science ®Google Scholar
• Slavova S, Rock P, Bush HM, Quesinberry D, Walsh SL. 2020. Signal of increased opioid overdose during COVID-19 from emergency medical services data. Drug Alcohol Depend. 214:108176.
   PubMed Web of Science ®Google Scholar
• Smith DM, Weitzel KW, Elsey AR, Langaee T, Gong Y, Wake DT, Duong BQ, Hagen M, Harle CA, Mercado E, et al. 2019. CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial. Genet Med. 21(8):1842–1850.
   PubMed Web of Science ®Google Scholar
• Solhaug V, Molden E. 2017. Individual variability in clinical effect and tolerability of opioid analgesics – importance of drug interactions and pharmacogenetics. Scand J Pain. 17:193–200.
   PubMed Web of Science ®Google Scholar
• Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I, et al. 2016. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 355:i4919.
   PubMed Web of Science ®Google Scholar
• Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, et al. 2019. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 366:l4898.
   PubMed Web of Science ®Google Scholar
• Takashina Y, Naito T, Mino Y, Yagi T, Ohnishi K, Kawakami J. 2012. Impact of CYP3A5 and ABCB1 gene polymorphisms on fentanyl pharmacokinetics and clinical responses in cancer patients undergoing conversion to a transdermal system. Drug Metab Pharmacokinet. 27(4):414–421.
   PubMed Web of Science ®Google Scholar
• Tanaka N, Naito T, Yagi T, Doi M, Sato S, Kawakami J. 2014. Impact of CYP3A5*3 on plasma exposure and urinary excretion of fentanyl and norfentanyl in the early postsurgical period. Ther Drug Monit. 36(3):345–352.
   PubMed Web of Science ®Google Scholar
• Taqi MM, Faisal M, Zaman H. 2019. OPRM1 A118G polymorphisms and its role in opioid addiction: implication on severity and treatment approaches. Pharmgenomics Pers Med. 12:361–368.
   PubMed Web of Science ®Google Scholar
• Victorri-Vigneau C, Verstuyft C, Bouquié R, Laforgue EJ, Hardouin JB, Leboucher J, Le Geay B, Dano C, Challet-Bouju G, Grall-Bronnec M. 2019. Relevance of CYP2B6 and CYP2D6 genotypes to methadone pharmacokinetics and response in the OPAL study. Br J Clin Pharmacol. 85(7):1538–1543.
   PubMed Web of Science ®Google Scholar
• Volkow ND, McLellan AT. 2016. Opioid abuse in chronic pain-misconceptions and mitigation strategies. N Engl J Med. 374(13):1253–1263.
   PubMed Web of Science ®Google Scholar
• Williams JT, Christie MJ, Manzoni O. 2001. Cellular and synaptic adaptations mediating opioid dependence. Physiol Rev. 81(1):299–343.
   PubMed Web of Science ®Google Scholar
• Wolking S, Schaeffeler E, Lerche H, Schwab M, Nies AT. 2015. Impact of genetic polymorphisms of ABCB1 (MDR1, P-glycoprotein) on drug disposition and potential clinical implications: update of the literature. Clin Pharmacokinet. 54(7):709–735.
   PubMed Web of Science ®Google Scholar
• Wu WD, Wang Y, Fang YM, Zhou HY. 2009. Polymorphism of the micro-opioid receptor gene (OPRM1 118A > G) affects fentanyl-induced analgesia during anesthesia and recovery. Mol Diag Ther. 13(5):331–337.
   PubMed Web of Science ®Google Scholar
• Yuan J-J, Hou J-K, Zhang W, Chang Y-Z, Li Z-S, Wang Z-Y, Du Y-Y, Ma X-J, Zhang L-R, Kan Q-C, et al. 2015. CYP3A4*1G genetic polymorphism influences metabolism of fentanyl in human liver microsomes in Chinese patients. Pharmacology. 96(1–2):55–60.
   PubMed Web of Science ®Google Scholar
• Yuferov V, Butelman ER, Randesi M, van den Brink W, Blanken P, van Ree JM, Kreek MJ. 2021. Association of serotonin transporter (SERT) polymorphisms with opioid dependence and dimensional aspects of cocaine use in a Caucasian cohort of opioid users. Neuropsychiatr Dis Treat. 17:659–670.
   PubMed Web of Science ®Google Scholar
• Zahari Z, Lee CS, Ibrahim MA, Musa N, Mohd Yasin MA, Lee YY, Tan SC, Mohamad N, Ismail R. 2016. Relationship between ABCB1 polymorphisms and serum methadone concentration in patients undergoing methadone maintenance therapy (MMT). Am J Drug Alcohol Abuse. 42(5):587–596.
   PubMed Web of Science ®Google Scholar
• Zhang W, Yuan JJ, Kan QC, Zhang LR, Chang YZ, Wang ZY, Li ZS. 2011. Influence of CYP3A5*3 polymorphism and interaction between CYP3A5*3 and CYP3A4*1G polymorphisms on post-operative fentanyl analgesia in Chinese patients undergoing gynaecological surgery. Eur J Anaesthesiol. 28(4):245–250.
   PubMed Web of Science ®Google Scholar
• Zhu F, Yan CX, Wen YC, Wang J, Bi J, Zhao YL, Wei L, Gao CG, Jia W, Li SB. 2013. Dopamine D1 receptor gene variation modulates opioid dependence risk by affecting transition to addiction. PLOS One. 8(8):e70805.
   PubMed Web of Science ®Google Scholar